An alphavirus-based therapeutic cancer vaccine: from design to clinical trial.
Amrita SinghGeorgia KoutsoumpliStephanie van de WallToos DaemenPublished in: Cancer immunology, immunotherapy : CII (2018)
Cancer immunotherapy has greatly advanced in recent years. Most immunotherapeutic strategies are based on the use of immune checkpoint blockade to unleash antitumor immune responses or on the induction or adoptive transfer of immune effector cells. We aim to develop therapeutic vaccines based on recombinant Semliki Forest virus vectors to induce tumor-specific effector immune cells. In this review, we describe our ongoing work on SFV-based vaccines targeted against human papillomavirus- and hepatitis C virus-related infections and malignancies, focusing on design, delivery, combination strategies, preclinical efficacy and product development for a first-in-man clinical trial with an HPV-specific vaccine.
Keyphrases
- clinical trial
- hepatitis c virus
- immune response
- dendritic cells
- cell therapy
- induced apoptosis
- regulatory t cells
- phase ii
- papillary thyroid
- open label
- study protocol
- human immunodeficiency virus
- cell cycle arrest
- double blind
- type iii
- climate change
- high grade
- phase iii
- cancer therapy
- randomized controlled trial
- mesenchymal stem cells
- squamous cell carcinoma
- oxidative stress
- cell proliferation
- endoplasmic reticulum stress
- gene therapy
- cell death
- inflammatory response
- hiv infected
- electron transfer
- cervical cancer screening